3 synthetic compounds have been temporarily placed into Schedule I.
The Departments of Health and Human Services (HHS) and Food and Drug Administration (FDA) commended the Drug Enforcement Administration’s (DEA) actions in response to kratom-related drug scheduling. Kratom, a plant from Southeast Asia, can be ingested orally to produce stimulant effects, while higher dosages lead to sedative effects for consumers.
In the first Notice of Intent, 3 synthetic 7-OH compounds in kratom will be temporarily placed in the Schedule I drug category, above a certain threshold. DEA also released a Request for Information, seeking public comment on scientific data regarding the drug’s threshold level and alternative measurements for consumption specifications.
DEA Administrator Terrance Cole said, “Today’s action targets highly concentrated, synthetic 7-OH products, which pose a growing threat to public safety and health. Temporarily scheduling these substances underscores the emphasis this Administration has put on the safety, health and well-being of the American people. This action gives law enforcement and public health partners the tools needed to address this emerging threat. We appreciate the FDA’s scientific expertise and our continued partnership with HHS to address emerging threats, and we will continue to act aggressively when dangerous substances threaten Americans.”
As the Lord Leads, Pray with Us…
- For Administrator Cole as he heads the DEA’s efforts to protect U.S. citizens against potentially dangerous drugs.
- For DEA officials involved in the research and response regarding these synthetic 7-OH substances, and publish conclusions on the substance’s regulatory standing and effects towards consumers.
Sources: Department of Health and Human Services
